해부 병리학 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Anatomic Pathology Market Summary

The global anatomic pathology market size was estimated at USD 34.72 billion in 2024 and is projected to reach USD 80.78 billion by 2033, growing at a CAGR of 9.79% from 2025 to 2033. Some of the major factors driving the market growth are rising global cancer and chronic disease burden, growing adoption of precision and personalized medicine, and digital pathology and artificial intelligence (AI) advancements.

For instance, in July 2025, PathAI (U.S.) launched the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories powered by PathAI's AISight 1 Image Management System (IMS). The PPN is intended to provide early access to the most recent AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, to allow participating laboratories to monetize real-world pathology data, to support biopharma-sponsored evidence generation studies, and to enable novel clinical development strategies that leverage AI-pathology. Furthermore, an aging population and rising healthcare expenditure fuel the growth of the global anatomic pathology industry. As per the World Population Prospects 2024, the world's population is expected to keep growing for another 50 or 60 years, peaking at around 10.3 billion in the mid-2080s, up from 8.2 billion in 2024.

The growth of molecular pathology and companion diagnostics (CDx) is significantly increasing the global market by allowing for more precise, personalized, and targeted approaches to disease diagnosis and treatment. Molecular pathology detects genetic, molecular, and cellular changes associated with specific diseases, most notably cancer, allowing for earlier and more accurate diagnoses. Companion diagnostics help guide the use of targeted therapies by identifying patients who are most likely to benefit from specific treatments. This combination of diagnostics and therapeutics is increasingly being used in oncology and other fields of medicine, driving demand for advanced pathology services. As pharmaceutical companies continue to invest in personalized medicine and regulatory agencies encourage the incorporation of CDx into drug development pipelines, the role of anatomic pathology is expanding beyond traditional histology to include molecular insights, accelerating market growth and innovation.

In addition to rising disease burdens and technological advancements, a number of other factors are driving the global anatomic pathology industry. The growing awareness and education of patients and healthcare providers about the importance of early and accurate diagnosis is driving up demand for pathology services. The growing number of biopsy procedures, driven by routine health screenings and preventive care programs, is increasing the demand for pathology analysis. Furthermore, the transition from hospital-based care to outpatient and specialized diagnostic centers improves pathology services' accessibility and efficiency. Favorable reimbursement policies in developed countries, as well as supportive government initiatives to strengthen diagnostic infrastructure in emerging economies, are further driving market growth.

Furthermore, strategic collaborations, mergers, and acquisitions between diagnostic labs, hospitals, and technology companies are fostering innovation and expanding service offerings across regions.

Global Anatomic Pathology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the anatomic pathology market report based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
  • Microtomes & Cryostat
  • Tissue Processors
  • Automatic Stainers
  • Whole Slide Imaging (WSI) Scanners
  • Other Products
• Consumables
  • Reagents & Antibodies
  • Probes & Kits
  • Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Disease Diagnosis
• Drug Discovery and Development
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Anatomic Pathology Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Anatomic Pathology Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product & Service Snapshot
• 2.3. Application Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Anatomic Pathology Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Global Cancer and Chronic Disease Burden
  • 3.4.2. Growing Adoption of Precision and Personalized Medicine
  • 3.4.3. Advancements in Digital Pathology and Artificial Intelligence (AI)
  • 3.4.4. Expansion of Molecular Pathology and Companion Diagnostics (CDx)
  • 3.4.5. Aging Population and Rising Healthcare Expenditure
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost of Advanced Diagnostic Equipment
  • 3.5.2. Stringent Regulatory and Compliance Requirements
  • 3.5.3. Data Privacy and Cybersecurity Issues
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Anatomic Pathology Market: Product & Service Estimates & Trend Analysis

• 4.1. Anatomic Pathology Market: Test Method Movement Analysis
• 4.2. Products
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.2. Microtomes & Cryostat
      • 4.2.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.3. Tissue Processors
      • 4.2.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.4. Automatic Stainers
      • 4.2.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.5. Whole Slide Imaging (WSI) Scanners
      • 4.2.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.6. Other Products
      • 4.2.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Consumables
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.2. Reagents & Antibodies
      • 4.2.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.3. Probes & Kits
      • 4.2.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.4. Others
      • 4.2.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Services

Chapter 5. Anatomic Pathology Market: Application Estimates & Trend Analysis

• 5.1. Anatomic Pathology Market: Mode Movement Analysis
• 5.2. Disease Diagnosis
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Drug Discovery and Development
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Others
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Anatomic Pathology Market: End Use Estimates & Trend Analysis

• 6.1. Anatomic Pathology Market: Product & Service Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Diagnostic Laboratories
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Research Laboratories
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Anatomic Pathology Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Anatomic Pathology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Danaher
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. PHC Holdings Corporation
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Quest Diagnostics Incorporated
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Laboratory Corporation of America Holdings
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. F. Hoffmann-La Roche AG
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Agilent Technologies, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Sakura Finetek USA, Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. NeoGenomics Laboratories, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. BioGenex
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bio SB
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives